Lotronex (TM) has been approved for marketing in the United States for the treatment of IBS in women whose predominant symptom is diarrhea. Lotronex (TM) has not yet been approved for marketing in Canada.
In most cases, IBS can be managed successfully without drugs. Current treatment for IBS include education, reassurance and diet.
While participants in clinical trials have reported improvements in a number of symptoms when taking Lotronex (TM), these trials have also shown a very high placebo response rate.
Some patients receiving Lotronex (TM) in the USA have reported serious adverse effects, including surgical complications of constipation, ischemic colitis and liver toxicity.